SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust (SLV) is experiencing a powerful, near-parabolic rally to fresh all-time highs, fueled by escalating industrial demand from sectors like EV batteries and clean energy, alongside looming Chinese export restrictions tightening global supply. This has sparked intense debate among investors, with many anticipating a monumental short squeeze and continued price discovery, while others caution the asset is severely overbought and due for a significant pullback.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending following FDA approval of its oral Wegovy, making it the first GLP-1 pill for weight management. The community sees this as a major catalyst, providing a convenient alternative to injections and positioning Novo Nordisk with a crucial edge in the rapidly expanding obesity treatment market against rivals like Eli Lilly. Investors are closely watching its market impact.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X is trending as the community eagerly anticipates its merger with Infleqtion, a key player in neutral-atom quantum technology. Recent catalysts like bullish analyst coverage and new strategic partnerships, particularly in defense and GPS-independent navigation, are fueling discussions that Infleqtion is significantly undervalued compared to its quantum peers, poised for substantial growth post-merger.

Ascent Solar Technologies, Inc. engages in the design, development, and manufacture of solar technology and power solutions for remote locations and extreme environments. It integrates photovoltaic modules into a variety of applications such as aerospace, defense, transportation, and electronic products. The company was founded by Mohan S. Misra and Joseph H. Armstrong on October 18, 2005 and is headquartered in Thornton, CO.

Ascent Solar Technologies Inc

Ascent Solar Technologies is currently trending due to a series of recent teaming agreements and product evaluations for its advanced thin-film photovoltaic modules, specifically for space and defense applications. The community is highly engaged, with many anticipating significant contracts and long-term growth in the burgeoning space economy, while a skeptical contingent highlights historical issues of dilution and speculative trading patterns.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore Corp. is trending due to federal regulatory approval for restarting the Las Flores Pipeline System, a critical development for its California offshore oil assets. This news is widely seen as a major de-risking event, with investors optimistic about bypassing state-level hurdles and the potential for a significant short squeeze. The community is actively discussing substantial upside potential, anticipating the restart of production to drive the stock higher.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is experiencing a significant surge in interest following announced high-grade silver drill results from its Vortex system, which is a key immediate catalyst. This news, combined with sustained share accumulation by Eric Sprott and a broader bullish sentiment in precious metals markets, is driving community discussions around the stock's future potential. Investors are actively debating the implications of these developments for the company's valuation and trajectory.

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in Sarnia, Canada.

Aduro Clean Technologies Inc

Aduro Clean Technologies is garnering significant attention following a successful $20 million offering and key milestones, including graduating Shell's GameChanger program and validating its hydrochemolytic process for converting waste plastics into high-value oils. This has sparked a polarized community debate, with many investors highlighting these advancements and new partnerships as strong indicators of future growth in the circular plastics market. Conversely, skeptics question the company's valuation and economic viability at scale, despite the technological progress.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience (RGC) is attracting significant attention, fueled by its extremely low share float and substantial insider ownership, which is sparking community discussions about a potential short squeeze. Traders are actively tracking its high cost to borrow and anticipating a surge, drawing comparisons to its past explosive runs despite acknowledged speculative fundamentals.

Starfighters Space Inc

Starfighters Space Inc. (FJET) is generating significant buzz due to extreme price volatility, fueling a fierce community debate. Bulls point to its low float and high shorting fees, anticipating a massive short squeeze, while skeptics warn of a pump-and-dump given its pre-revenue status and high market valuation. The ongoing battle between buyers and sellers, coupled with calls of market manipulation, keeps this aerospace-related ticker actively discussed.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending due to significant community discussion around federal cannabis reclassification and the perceived removal of the 280E tax barrier, which is seen as a massive catalyst for the industry. This "Green Wave" narrative, largely driven by the WEEDCOIN token within the Solana ecosystem, positions the network as a leading platform for on-chain cannabis finance due to its speed and efficiency, attracting considerable retail enthusiasm.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Best Penny Stocks To Consider - December 10th

iBio, iBio, Momentus, Bitfarms, Richtech Robotics, Bit Digital, and Strive are the seven Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are low-priced shares...

Top Manufacturing Stocks To Keep An Eye On - December 10th

Taiwan Semiconductor Manufacturing, Applied Materials, Johnson Controls International, Flex, iBio, FREYR Battery, and Fabrinet are the seven Manufacturing stocks to watch today, according to...

Manufacturing Stocks To Research - December 8th

Taiwan Semiconductor Manufacturing, Applied Materials, Flex, Johnson Controls International, and iBio are the five Manufacturing stocks to watch today, according to MarketBeat's stock screener tool...

Best Biotech Stocks To Keep An Eye On - December 8th

WAVE Life Sciences, Vertex Pharmaceuticals, iBio, argenex, and Cidara Therapeutics are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares...

iBio, Inc. (IBIO) Reports Q1 Loss

iBio (IBIO) delivered earnings and revenue surprises of -57.14% and 0.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of iBio, Inc.(IBIO) were in the spotlight on Monday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/04/07/3056559/0/en/iBio-Announces-IBIO-600-Non-Human-Primate-Data-Showing-Extended-Half-Life-and-Muscle-Growth-and-Interim-In-Vivo-Results-for-First-in-Class-Activin-E-Antibody-Advancing-Cardiometabo.html">announced</a> positive data from a study conducted in animals for its lead asset IBIO-600.The company said data from a study on elderly and obese non-human primates shows that the anti-myostatin antibody could provide a weight loss treatment option while preserving and promoting muscle growth.The study consisted of a single administration of two dose levels: 5mg/kg and a high dose of 50mg/kg.Shares of the company were down by over 43% on Monday noon amid a broader market decline.Notably, the study does not prove statistical significance and only involves a single administration of the antibody.However, the study demonstrated an extended half-life for the antibody, potentially enabling a once three to six-month dosing schedule in humans, the company said.CEO Martin Brenner said the company is on track for a regulatory submission for the antibody in the first quarter (Q1) of 2026.iBio in-licensed IBIO-600 from AstralBio, Inc. in January. The company paid AstralBio $750,000 by issuing its common stock as an upfront payment and said AstralBio will also be eligible for development and commercialization milestone payments totaling up to $28 million.On Monday, the company also announced preclinical data for an Activin E antibody and said that the antibody showed positive results in an exploratory study with obese mice, highlighting its potential as a treatment for obesity.On Stocktwits, retail sentiment about iBio remained in the ‘bearish’ territory while message volume rose marginally within ‘low’ levels over the past 24 hours.<figure class="image"><img style="aspect-ratio:654/152;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_07_at_11_29_58_AM_png_24aaec3e9f.webp" alt="IBIO's Sentiment Meter and Message Volume as of 11:30 a.m. ET on April 7, 2025 | Source: Stocktwits" width="654" height="152"><figcaption>IBIO's Sentiment Meter and Message Volume as of 11:30 a.m. ET on April 7, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed surprise at the stock’s downward trajectory.<stembedurl>https://stocktwits.com/Skypier2/message/610731384</stembedurl>Another opined that the company needs to protect itself against any potential hostile takeovers.<stembedurl>https://stocktwits.com/dcpanda/message/610733604</stembedurl><a href="https://stocktwits.com/symbol/IBIO">iBio shares</a> are down by over 24% this year and by over 19% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/federal-reserve-board-of-governors-will-meet-today/chf1DjqRb7o">Federal Reserve Board Of Governors Will Meet Today — Traders Factor In 4 Rate Cuts This Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

iBio Stock Plummets Despite Positive Data On Weight-Loss Treatment Antibody: Retail Stays Bearish

However, the company said that the study does not prove statistical significance and only involves a single administration of the antibody. 

Equity

Biotechs have underperformed the broader market this year, and these stock are at crossroads as they await the new administration under Donald Trump to take over shortly after the new year.The SPDR S&amp;P Biotech ETF ($XBI) has gained 9.2% for the year-to-date period compared to the 25%+ gain for the S&amp;P 500 Index. The iShares Biotechnology ETF ($IBB), which has a relatively higher proportion of mid- and large-cap stocks, has also added under 10% so far this year.The underperformance takes away the sheen of the industry’s defensive credentials.&nbsp;R&amp;D momentum slowed during the year, as is evident from the new molecular entity approvals, which number 38 so far this year compared to 47 for the same period last year.&nbsp;&nbsp;Most biotech companies operate deep in the red for a very long time until they could begin commercializing products. They rely on debt financing which came to be expensive in an elevated interest rate environment.&nbsp;With a change of guard on the political arena following Trump's win, the outlook for the industry is yet unclear.Morgan Stanley Head of Policy Monica Guerra&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.morganstanley.com/articles/trump-re-election-implications-for-markets">said&nbsp;</a>in a recent note that deregulation is likely to be a major theme expected during the second term. “Less stringent requirements in pharmaceuticals and biotechnology, meanwhile, could help those industries by prompting accelerated drug approvals,” she said.BMO Capital Markets analyst Evan Seigerman said the election results are “modestly positive” for the biopharma sector,&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fiercepharma.com/pharma/trump-white-house-again-whats-ahead-pharma">according</a> to FiercePharma. The analyst sees potential deprioritization of the Internal Revenue Service, likely less Federal Trade Commission interference, and lower corporate taxes.Jefferies analysts does not expect the proposed drug pricing reforms to pass as the Republican legislators are divided over the proposals.Amid the ongoing discussions about the implications of Trump’s presidency, here’s a few biopharma stocks that are on retail’s radar (based on the number of followers on the Stocktwits platform):Moderna, Inc. ($ MRNA): 107,109 watchersNovavax, Inc. ($NVAX): 101,846Pfizer, Inc. ($PFE): 99,425 watchersiBio, Inc. ($IBIO): 93,617 watchersInovia Pharma, Inc. ($INO): 93,414 watchersJaguar Health ($JAGX): 81,859 watchersGilead Sciences, Inc. ($GILD): 77,094 watchersVaxart, Inc. ($VXRT): 75,807 watchersTonix Pharmaceutical Holding Corp. ($TNXP): 72,666 watchersSorrento Therapeutics, Inc. ($SRNE): 68,474 watchersRead Next:&nbsp; <a href="https://stocktwits.com/news-articles/markets/equity/block-ceo-jack-dorsey-weighs-in-on-election-impact/cJ4EMJ3Raj">Block CEO Jack Dorsey Keeps Fingers Crossed Over Regulatory Environment As Trump Makes A Comeback</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

GOP lawmakers are divided over drug pricing reforms.

Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching

Less stringent requirements in pharmaceuticals and biotechnology could help by prompting accelerated drug approvals.

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

IBIO
iBio Inc

Feed

News

Sentiment

Fundamentals

Info

Latest IBIO News

IBIOiBio Inc